VGX 3100

Drug Profile

VGX 3100

Alternative Names: Human papillomavirus vaccine-VGX Pharmaceuticals; VGX-3100

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical intraepithelial neoplasia
  • Phase II Anal intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia
  • No development reported Head and neck cancer

Most Recent Events

  • 06 Aug 2018 Inovio Pharmaceuticals and AIDS Malignancy Consortium plans a phase II trial for Anal intraepithelial neoplasia (Late-stage disease) in USA in September 2018 (NCT03603808)
  • 20 Jul 2018 Phase-III clinical trials in Cervical intraepithelial neoplasia in Canada, United Kingdom, Portugal, Peru, Italy, Germany, Finland and Belgium (IM) (NCT03185013) (EudraCT2016-002761-63)
  • 28 May 2018 No recent reports of development identified for clinical-Phase-Unknown development in Head-and-neck-cancer in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top